Gossamer Bio

Pharma

Aerovate's stock plummets after sole product fails in PAH trial

The company is scrapping future development of its lead and only program, an inhaled version of Novartis' Gleevec, in pulmonary arterial hypertension.

Zoey Becker Jun 17, 2024 7:25pm

Gossamer poaches Merck’s Bob Smith as its new commercial lead

Dec 5, 2023 7:51am